Clinical Trial Update: Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Thymoglobulin, Alemtuzumab, and Daclizumab as induction therapies in living-donor renal transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Daclizumab (daclizumab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University of Miami | Conditions: End-Stage Renal Disease, Living Donors | Phase 4 | Status: COMPLETED